DEEP RESEARCH · GALDERMA

Galderma: Global Re-Rating of a Pure-Play Dermatology Platform

A full-platform view of injectables, dermocosmetics, therapeutics, growth, and valuation risk.

Published: 2026-01-23 · Global aesthetics and therapeutic dermatology lens · Original Naver Blog

0. Bottom line first

Official fact: The source says Galderma began in 1981 as a Nestlé and L'Oréal joint venture and entered a re-rating phase after its March 2024 SIX listing. 2025 nine-month net sales were USD 3.737bn, up 15.0% YoY at constant currency.

Interpretation: Galderma’s premium is about portfolio and channel, not one product. Nemluvio strengthens therapeutics, Restylane and Sculptra defend premium aesthetics, and GAIN training locks in physician behavior. But a 30-40x 2026E PER requires a clear view of EQT overhang, China risk, and therapeutic competition.

1. Revenue mix: the three-pillar structure

Galderma’s 2025 nine-month sales were USD 3.737bn, up 15.0% YoY at constant currency. The source interprets this as evidence that dermatology demand remains resilient even with macro concerns.

Official fact: Galderma is present in more than 90 countries. The source cites 17.5% 9M25 growth in the U.S. and 13.2% growth in international markets including China and Brazil.

Interpretation: Therapeutic growth is the most important swing factor. If drugs like Nemluvio lower the cyclicality of aesthetic injectables, Galderma can be valued more like a high-margin pharmaceutical dermatology company.

2. Technology moat: NASHA, OBT, Sculptra, Relfydess

Restylane offers physicians two different toolkits: NASHA for structural support and OBT for flexible, natural integration. Sculptra is positioned against PDLA competitors by emphasizing PLLA crystallinity, slower degradation, and volume effect lasting more than two years.

Interpretation: New entrants can compete on price, but it is much harder to copy 20+ years of clinical data, physician training, and brand trust at the same time. Galderma’s moat is as much “the familiar standard in the injector’s hand” as it is product chemistry.

3. Production and supply chain: the physical base

The source says Galderma produces more than 330 million products annually through four major global production sites.

Official fact: The source says Galderma plans to invest USD 650mn, about KRW 900bn, by 2030 to expand U.S. manufacturing capacity. It also discusses a potential fifth plant in Singapore to serve Asia-Pacific demand.

Interpretation: If Nemluvio becomes a true blockbuster, fill-finish and packaging capacity must not become a bottleneck. The U.S. investment and Singapore plan are insurance for therapeutics and Asian growth.

4. Lock-in strategy: Ozempic face and GAIN

The spread of GLP-1 obesity drugs has created demand for treating facial volume loss and aging, often called Ozempic face. The source says Galderma developed the SHAPE Up protocol combining Sculptra and Restylane Lyft and ran clinical work around it.

Official fact: The source says 89% of patients were more satisfied with their appearance after treatment, with significant improvement in skin thickness and elasticity. GAIN(Global Aesthetic Injector Network) is described as running more than 10,000 training events per year and educating more than 110,000 healthcare professionals.

Interpretation: GAIN is not ordinary marketing. It is channel infrastructure that creates recurring revenue. Once physicians become familiar with injection feel and technique, switching to low-cost alternatives becomes harder.

5. Financials and cash flow

9M25 sales were about USD 3.74bn, up 15.0%, and the source says the company is tracking toward the high end of full-year growth guidance of 17.0-17.7%. Core EBITDA margin is guided at 23.1-23.6% for 2025 and could expand to 26-28% by 2027.

6. China, the U.S., and governance risk

In China, Galderma mixes direct presence with partnerships. The source discusses 2024 Sculptra NMPA approval, Restylane lineup expansion, Alastin launch, designated e-commerce channels, and authenticity campaigns to manage grey-market imports. In the U.S., after 2024 FDA approval for Nemluvio, the company is using DTC campaigns and dermatologist networks to drive prescriptions.

On governance, EQT block trades are the near-term supply issue. The source says EQT sold 17mn shares in July 2025 and 20mn shares in October 2025. L'Oréal increasing its stake to 20% is viewed positively for long-term stability, and the source notes a typical 90-day lock-up on remaining EQT shares, supporting orderly sales.

7. Valuation and scenarios

Galderma trades at roughly 30-40x 2026E PER in the source, while Korean peers such as PharmaResearch and Hugel are described at roughly 15-20x. The premium is attributed to distribution across more than 90 countries, FDA/EMA/NMPA credibility, innovative biologics, and more than 40 years of brand heritage.

Bull Case

• Nemluvio becomes a blockbuster and raises the therapeutic mix.
• Ozempic-face demand expands Sculptra and Restylane combination treatments.
• L'Oréal’s participation reduces EQT overhang and improves long-term confidence.

Bear Case

• U.S.-China trade tensions could hit China sales.
• Competing Nemluvio alternatives could compress therapeutic margins and growth expectations.
• Remaining EQT stake sales could create temporary supply pressure.

Official fact: The source’s conclusion is Strong Buy, with a 2026 consensus-based target of CHF 165-190 and about 15-30% upside from the then-current price.

Interpretation: I would treat that conclusion as a checklist rather than a standalone recommendation: the premium is justified only if Nemluvio, China, GAIN lock-in, and margin expansion all keep tracking.